| Chemical Information | |
| Antiviral agent ID | DrugRepV_4487 | |
| Antiviral agent name | CMX029 | |
| IUPAC Name | ({[(2R)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)[3-(hexadecyloxy)propoxy]phosphinic acid |  |
| SMILES (isomeric) | CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@@H](CO)CN1C=CC(N)=NC1=O | |
| Molecular Formula | C27H52N3O7P | |
| Molecular Weight (g/mol) | 561.701 | |
| InChl | InChI=1/C27H52N3O7P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-35-20-16-21-37-38(33,34)24-36-25(23-31)22-30-18-17-26(28)29-27(30)32/h17-18,25,31H,2-16,19-24H2,1H3,(H,33,34)(H2,28,29,32)/t25-/s2 | |
| Structural Information | |
 |
|
| Clinical Information | |
| Biological Information | |
|
Secondary Indication | Ebola virus (EBOV) NA EBOV-GFP |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | In-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Pre infection
| |
|
Secondary Indication (Duration of drug delivery) | 2 days (48 hours)
| |
|
Secondary Indication (Drug concentration) | 0.271 ± 0.76 μM
| |
|
Secondary Indication (Cell based assay) | Luciferase assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | EC50 [ 50 % ] | |
|
Secondary Indication (Cytotoxicity) | 9.40 ± 1.01 μM | |
|
Reference | McMullan LK, Flint M, Dyall J, Albariņo C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF..The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus..Antiviral Res. 2016 Jan;125:71-8. doi: 10.1016/j.antiviral.2015.10.010. Epub 2015 Oct 23. PMID:26526586
|  |
|
Comment | The antiviral activity was associated with the HDP lipid moiety which was necessary for potent in vitro activity of BCV against EBOV.
| |